Physician profile
Rosanna Garner
NPI 1770617276
$2,412.08
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $259 · 2021: $553 · 2022: $661 · 2023: $422 · 2024: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.50 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.99 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $251.93 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $211.13 | 2020-2021 | |
| Pfizer INC. | $200.82 | 2023-2024 | |
| Avanir Pharmaceuticals, INC. | $177.96 | 2019-2022 | |
| Allergan, INC. | $163.02 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $157.22 | 2022 | |
| Medtronic, INC. | $147.83 | 2024 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $145.31 | 2019-2024 | Austedo Xr, Ajovy |
| Nevro Corp. | $86.57 | 2023 | Senza |
| Lilly USA, LLC | $55.74 | 2020-2023 | Emgality, Reyvow |
| Amgen INC. | $50.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.93 | 2019 | |
| Assertio Therapeutics, INC. | $31.64 | 2019-2020 | |
| Tersera Therapeutics LLC | $31.58 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $13.54 | 2022 | |
| Impel Pharmaceuticals INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosanna Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.